Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 5000.00 | 3570.27 | 6079.00 | 5872.75 | 1.0351 | 1.0985 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 5000.00 | 3570.27 | 2887.00 | 5872.75 | 0.4916 | -0.2561 |
| SK-BR-3 | 0 | uM | 9 | 5000.00 | 3570.27 | 5860.00 | 5872.75 | 0.9978 | 0.9940 | |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 132.00 | 123.25 | 1.0710 | 1.3583 | |
| SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 156.25 | 92.36 | 136.00 | 123.25 | 1.1034 | 1.5337 |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 156.25 | 92.36 | 126.00 | 123.25 | 1.0223 | 1.1089 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 156.25 | 92.36 | 105.00 | 123.25 | 0.8519 | 0.3608 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 156.25 | 92.36 | 122.00 | 123.25 | 0.9899 | 0.9516 |
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 156.25 | 92.36 | 80.00 | 123.25 | 0.6491 | -0.2920 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 167.00 | 123.25 | 1.3550 | 3.1498 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 156.25 | 92.36 | 153.00 | 123.25 | 1.2414 | 2.3625 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 152.00 | 123.25 | 1.2333 | 2.3099 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 156.25 | 92.36 | 69.00 | 123.25 | 0.5598 | -0.5038 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 156.25 | 92.36 | 130.00 | 123.25 | 1.0548 | 1.2734 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 124.00 | 123.25 | 1.0061 | 1.0294 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 156.25 | 92.36 | 127.00 | 123.25 | 1.0304 | 1.1493 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 156.25 | 92.36 | 130.00 | 123.25 | 1.0548 | 1.2734 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 189.00 | 123.25 | 1.5335 | 4.5868 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 156.25 | 92.36 | 109.00 | 123.25 | 0.8844 | 0.4887 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 103.00 | 123.25 | 0.8357 | 0.2994 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 156.25 | 92.36 | 159.00 | 123.25 | 1.2901 | 2.6881 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 94.00 | 123.25 | 0.7627 | 0.0431 | |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 156.25 | 92.36 | 128.00 | 123.25 | 1.0385 | 1.1902 |
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 156.25 | 92.36 | 112.00 | 123.25 | 0.9087 | 0.5891 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 104.00 | 123.25 | 0.8438 | 0.3299 |